Overview
APC-related attenuated familial adenomatous polyposis (AFAP) is a hereditary colorectal cancer predisposition syndrome caused by pathogenic variants in the APC (adenomatous polyposis coli) gene. This entry in Orphanet is marked as OBSOLETE, meaning it has been retired and its content has been merged into or replaced by a broader or updated classification. AFAP is now generally classified under the broader entity of familial adenomatous polyposis (FAP) or APC-associated polyposis conditions. In its clinical presentation, AFAP is characterized by the development of fewer colorectal adenomatous polyps than classic FAP — typically between 10 and 100 cumulative adenomas, compared to hundreds or thousands in classic FAP. Polyps tend to appear later in life, often in the third to fourth decade, and are frequently located in the proximal (right-sided) colon. Despite the reduced polyp burden, individuals with AFAP still carry a significantly elevated lifetime risk of colorectal cancer if left unmonitored, with cancer typically developing approximately 10–15 years later than in classic FAP. Upper gastrointestinal polyps, particularly duodenal adenomas and fundic gland polyps of the stomach, may also occur. Extraintestinal manifestations such as desmoid tumors and osteomas are less common than in classic FAP but can occur. Management of AFAP involves regular colonoscopic surveillance beginning in the late teenage years or early twenties, with polypectomy of detected adenomas. When polyp burden becomes too great for endoscopic management, surgical options including colectomy with ileorectal anastomosis may be recommended. Upper gastrointestinal endoscopy is also advised for duodenal polyp surveillance. Genetic counseling is recommended for affected individuals and at-risk family members. Patients are encouraged to consult current Orphanet and clinical guidelines, as this specific entry has been retired in favor of updated disease classifications.
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: APC-related attenuated familial adenomatous polyposis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: APC-related attenuated familial adenomatous polyposis at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: APC-related attenuated familial adenomatous polyposis.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: APC-related attenuated familial adenomatous polyposis.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: APC-related attenuated familial adenomatous polyposis.
Start the conversation →Latest news about OBSOLETE: APC-related attenuated familial adenomatous polyposis
No recent news articles for OBSOLETE: APC-related attenuated familial adenomatous polyposis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about OBSOLETE: APC-related attenuated familial adenomatous polyposis
What is OBSOLETE: APC-related attenuated familial adenomatous polyposis?
APC-related attenuated familial adenomatous polyposis (AFAP) is a hereditary colorectal cancer predisposition syndrome caused by pathogenic variants in the APC (adenomatous polyposis coli) gene. This entry in Orphanet is marked as OBSOLETE, meaning it has been retired and its content has been merged into or replaced by a broader or updated classification. AFAP is now generally classified under the broader entity of familial adenomatous polyposis (FAP) or APC-associated polyposis conditions. In its clinical presentation, AFAP is characterized by the development of fewer colorectal adenomatous
How is OBSOLETE: APC-related attenuated familial adenomatous polyposis inherited?
OBSOLETE: APC-related attenuated familial adenomatous polyposis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: APC-related attenuated familial adenomatous polyposis typically begin?
Typical onset of OBSOLETE: APC-related attenuated familial adenomatous polyposis is adult. Age of onset can vary across affected individuals.